Apatorsen
- Generic Name
- Apatorsen
- Drug Type
- Biotech
- CAS Number
- 1002331-21-6
- Unique Ingredient Identifier
- IFJ6X26JW6
- Background
Apatorsen is a second generation antisense drug which in preclinical experiments, inhibits production of Heat Shock Protein 27 (Hsp27) a cell survival protein found at elevated levels in many human cancers including prostate, lung, breast, ovarian, bladder, renal, pancreatic, multiple myeloma and liver cancer.
- Indication
Investigated for use/treatment in cancer/tumors (unspecified).
Study of Gemcitabine/Carboplatin First-line Chemotherapy +/- Apatorsen in Advanced Squamous Cell Lung Cancers
- Conditions
- Squamous Cell Lung Cancer
- Interventions
- First Posted Date
- 2015-04-22
- Last Posted Date
- 2017-08-22
- Lead Sponsor
- Queen Mary University of London
- Target Recruit Count
- 140
- Registration Number
- NCT02423590
- Locations
- 🇬🇧
Medway NHS Foundation Trust, Gillingham, Kent, United Kingdom
🇬🇧Barts Health NHS Trust, London, United Kingdom
🇬🇧University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom
Phase II Trial Of Gemcitabine Plus Nab-Paclitaxel +/- OGX-427 In Patients With Metastatic Pancreatic Cancer
- First Posted Date
- 2013-05-01
- Last Posted Date
- 2017-05-16
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 132
- Registration Number
- NCT01844817
- Locations
- 🇺🇸
Florida Cancer Specialists-South, Ft. Myers, Florida, United States
🇺🇸Florida Hospital Cancer Insitute, Orlando, Florida, United States
🇺🇸Ingalls Cancer Research Center, Harvey, Illinois, United States
Phase II Trial of Carboplatin and Pemetrexed +/- OGX-427 in Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer
- Conditions
- Non Squamous Non Small Cell Lung Cancer
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-04-11
- Last Posted Date
- 2018-06-08
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 155
- Registration Number
- NCT01829113
- Locations
- 🇺🇸
Tennessee Oncology, Nashville, Tennessee, United States
🇺🇸Florida Cancer Specialists-South, Fort Myers, Florida, United States
🇺🇸Oncology Hematology Care, Inc., Cincinnati, Ohio, United States
Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer
- Conditions
- Bladder CancerUrothelial Carcinoma
- Interventions
- First Posted Date
- 2013-01-31
- Last Posted Date
- 2022-07-11
- Lead Sponsor
- Noah Hahn, M.D.
- Target Recruit Count
- 200
- Registration Number
- NCT01780545
- Locations
- 🇺🇸
UCLA: Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸University of Maryland: Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸Siteman Cancer Center, Saint Louis, Missouri, United States
OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone
- Conditions
- Prostate CancerMetastatic Castrate-Resistant Prostate CancerPSA
- Interventions
- First Posted Date
- 2012-09-10
- Last Posted Date
- 2022-07-11
- Lead Sponsor
- Costantine Albany
- Target Recruit Count
- 72
- Registration Number
- NCT01681433
- Locations
- 🇺🇸
IU Health Central Indiana Cancer Centers, Indianapolis, Indiana, United States
🇺🇸Prostate Oncology Specialists, Inc., Marina Del Rey, California, United States
🇺🇸IU Health Goshen Hospital, Goshen, Indiana, United States
OGX-427 in Castration Resistant Prostate Cancer Patients
- Conditions
- Castration Resistant Prostate Cancer
- Interventions
- First Posted Date
- 2010-05-11
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- British Columbia Cancer Agency
- Target Recruit Count
- 74
- Registration Number
- NCT01120470
- Locations
- 🇨🇦
CancerCare Manitoba, Winnipeg, Manitoba, Canada
🇨🇦BC Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada
🇨🇦BC Cancer Agency - Centre for the Southern Interior, Kelowna, British Columbia, Canada
A Study for Treatment of Superficial Bladder Cancer Using OGX-427
- Conditions
- Bladder Cancer
- First Posted Date
- 2009-08-17
- Last Posted Date
- 2012-02-13
- Lead Sponsor
- Vancouver Coastal Health
- Target Recruit Count
- 36
- Registration Number
- NCT00959868
- Locations
- 🇨🇦
The Prostate Centre at Vancouver General Hospital, Vancouver, British Columbia, Canada
Safety Study of an Antisense Product in Prostate, Ovarian, NSCL, Breast or Bladder Cancer
- First Posted Date
- 2007-06-19
- Last Posted Date
- 2016-01-18
- Lead Sponsor
- Achieve Life Sciences
- Target Recruit Count
- 64
- Registration Number
- NCT00487786
- Locations
- 🇨🇦
BC Cancer Agency, Vancouver, British Columbia, Canada
🇨🇦Juravinski Cancer Center, Hamilton, Ontario, Canada
🇺🇸Seattle Cancer Care Alliance, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.